Facebook Twitter Google+ LinkedIn Email PrintBOULDER — Biotech startup Muse Biotechnology Inc. has raised $23 million in new equity Series B financing. The funding was reported in a Regulation D filing with the U.S. Securities and Exchange Commission, Feb. 28, and was led by Venrock, a venture-capital firm based in Palo Alto, Calif., according to a company press release. Other investors included Foresite Capital and Paladin Capital, as well as Series A investors, NanoDimension and…
